|
CBFA2T2 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.62447832963153E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
1.03361763592602E-13 |
| Normal-vs-Stage2 |
1.92633999999137E-05 |
| Normal-vs-Stage3 |
2.20934381900406E-14 |
| Normal-vs-Stage4 |
6.65859589688012E-11 |
| Stage1-vs-Stage2 |
1.532020E-01 |
| Stage1-vs-Stage3 |
5.156000E-02 |
| Stage1-vs-Stage4 |
6.417900E-02 |
| Stage2-vs-Stage3 |
7.521800E-03 |
| Stage2-vs-Stage4 |
9.964800E-03 |
| Stage3-vs-Stage4 |
7.088800E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
1.11022302462516E-15 |
| Normal-vs-AfricanAmerican |
4.45279999999881E-05 |
| Normal-vs-Asian |
5.17099996155679E-09 |
| Caucasian-vs-AfricanAmerican |
5.245000E-01 |
| Caucasian-vs-Asian |
5.754800E-01 |
| AfricanAmerican-vs-Asian |
7.493000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
6.07491834614393E-12 |
| Normal-vs-Female |
1.62503344114384E-12 |
| Male-vs-Female |
5.751800E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
2.29870011914102E-10 |
| Normal-vs-Age(41-60Yrs) |
1.044797581784E-11 |
| Normal-vs-Age(61-80Yrs) |
3.18609583160878E-11 |
| Normal-vs-Age(81-100Yrs) |
1.220300E-04 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
9.962000E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
8.064000E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
1.673960E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
8.280800E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
2.751400E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
2.594000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
2.63089999996691E-06 |
| Classical-VS-Follicular |
4.356100E-02 |
| Classical-VS-Other |
5.703000E-01 |
| Classical-VS-Normal |
5.69229996472131E-10 |
| Tall-VS-Follicular |
2.13530000015005E-07 |
| Tall-VS-Other |
1.900970E-01 |
| Tall-VS-Normal |
5.99520433297585E-15 |
| Follicular-VS-Other |
8.411200E-01 |
| Follicular-VS-Normal |
3.00040000000834E-06 |
| Other-VS-Normal |
2.941800E-01 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
2.31281660489913E-12 |
| Normal-vs-N1 |
9.81309478120806E-11 |
| N0-vs-N1 |
5.625500E-02 |
|
|
